Basel Area Business & Innovation inks new collaboration with Korean biopharma companies
May 6, 2026 | Wednesday | News
Agreement aims to be a flagship programme that bridges Korea and the global market
image credit- Roche Korea
Basel Area Business & Innovation, the strategic growth partner helping ventures in science and tech to land, launch and level up inside Europe’s transformative life sciences supercluster, has announced a new collaboration with leading Korean biopharmas.
The partnership with Roche Korea, the Korea Health Industry Development Institute (KHIDI), and the Korea Technology Finance Corporation (KIBO) will help high-potential biopharma companies expand into global markets, including the United States.
This collaboration demonstrates a new model for international ecosystem building, one that combines market access, industry expertise, and increased collaboration. At its core, the partnership is about creating a clearer, faster path for Korean biotech and pharmaceutical companies to access global expertise, capital, and infrastructure, while also building stronger connections with key innovation markets across the globe.
The partners will launch a joint open innovation program beginning in May 2026, starting with selected participating companies. Each organization brings a distinct role:
Roche Korea will lead company selection and explore opportunities for funding, mentoring, and collaboration.
KHIDI will promote and help operate the program, identifying strong candidates.
KIBO will evaluate companies and support access to financing to help accelerate growth.
Basel Area Business & Innovation will connect companies to the Basel Area Life Sciences Supercluster and provide access to infrastructure, including the Switzerland Innovation Park Basel Area.